Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1998052937) 4-ARYL-3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS P38 KINASE
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/1998/052937 International Application No.: PCT/US1998/010807
Publication Date: 26.11.1998 International Filing Date: 22.05.1998
Chapter 2 Demand Filed: 16.12.1998
IPC:
C07D 401/04 (2006.01) ,C07D 401/14 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
Applicants:
ANANTANARAYAN, Ashok [US/US]; US (UsOnly)
CLARE, Michael [GB/US]; US (UsOnly)
GENG, Lifeng [CN/US]; US (UsOnly)
HANSON, Gunnar, J. [US/US]; US (UsOnly)
PARTIS, Richard, A. [US/US]; US (UsOnly)
STEALEY, Michael, A. [US/US]; US (UsOnly)
WEIER, Richard, M. [US/US]; US (UsOnly)
G.D. SEARLE AND CO. [US/US]; P.O. Box 5110 Chicago, IL 60680, US (AllExceptUS)
Inventors:
ANANTANARAYAN, Ashok; US
CLARE, Michael; US
GENG, Lifeng; US
HANSON, Gunnar, J.; US
PARTIS, Richard, A.; US
STEALEY, Michael, A.; US
WEIER, Richard, M.; US
Agent:
WILLIAMS, Scott, A. ; Senniger, Powers, Leavitt & Roedel 16th floor F1 One Metropolitan Square St. Louis, MO 63102, US
Priority Data:
60/047,53522.05.1997US
Title (EN) 4-ARYL-3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS P38 KINASE
(FR) PYRAZOLES 3(5)-HETEROARYL SUBSTITUEES UTILISEES COMME INHIBITEURS DE KINASE p38
Abstract:
(EN) A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (I), wherein R1 and R2 are as described in the specification; and Ar1 is aryl optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, alkyldioxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, aminocarbonyl, cyano, alkoxycarbonyl, formyl, aminosulfonyl, alkylamino, nitro, arylamino, alkylcarbonylamino, halosulfonyl, aminoalkyl, and haloalkyl; and HetAr2 is pyridinyl, pyrimidinyl or quinolinyl optionally substituted with one or more radicals independently selected from alkylthio, alkylsulfonyl, alkylsulfinyl, halo, alkyl, heterocyclyl, alkoxy, aralkoxy, haloalkyl, amino, cyano, aralkyl, alkylamino, cycloalkylamino, cycloalkenylamino, arylamino, alkynylamino, and aralkylamino; or a pharmaceutically-acceptable salt or a tautomer thereof.
(FR) La présente invention concerne une classe de dérivés de pyrazole destinés à traiter les troubles dont le médiateur est la kinase p38. Des composés présentant un intérêt particulier sont définis dans la formule (I) dans laquelle R1, R2, Ar1 et HetAr2 sont tels que définis dans la description.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)